Can peri-ovulatory putrescine supplementation improve egg quality in older infertile women?

Yong Tao, Alina Tartia, Maralee Lawson, Mary Zelinski, Wei Wu, Jia Yin Liu, Johan Smitz, Marie Claude Léveillé, Arthur Leader, Hongmei Wang, Timothy Ramsay, X. Johné Liu

    Research output: Contribution to journalArticle

    Abstract

    The aging-related decline in fertility is an increasingly pressing medical and economic issue in modern society where women are delaying family building. Increasingly sophisticated, costly, and often increasingly invasive, assisted reproductive clinical protocols and laboratory technologies (ART) have helped many older women achieve their reproductive goals. Current ART procedures have not been able to address the fundamental problem of oocyte aging, the increased rate of egg aneuploidy, and the decline of developmental potential of the eggs. Oocyte maturation, which is triggered by luteinizing hormone (LH) in vivo or by injection of human chorionic gonadotropin (hCG) in an in vitro fertilization (IVF) clinic, is the critical stage at which the majority of egg aneuploidies arise and when much of an egg’s developmental potential is established. Our proposed strategy focuses on improving egg quality in older women by restoring a robust oocyte maturation process. We have identified putrescine deficiency as one of the causes of poor egg quality in an aged mouse model. Putrescine is a biogenic polyamine naturally produced in peri-ovulatory ovaries. Peri-ovulatory putrescine supplementation has reduced egg aneuploidy, improved embryo quality, and reduced miscarriage rates in aged mice. In this paper, we review the literature on putrescine, its occurrence and physiology in living organisms, and its unique role in oocyte maturation. Preliminary human data demonstrates that there is a maternal aging-related deficiency in ovarian ornithine decarboxylase (ODC), the enzyme responsible for putrescine production. We argue that peri-ovulatory putrescine supplementation holds great promise as a natural and effective therapy for infertility in women of advanced maternal age, applicable in natural conception and in combination with current ART therapies.

    Original languageEnglish (US)
    JournalJournal of Assisted Reproduction and Genetics
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Putrescine
    Ovum
    Oocytes
    Aneuploidy
    Eggs
    Biogenic Polyamines
    Medical Economics
    Ornithine Decarboxylase
    Maternal Age
    Spontaneous Abortion
    Chorionic Gonadotropin
    Fertilization in Vitro
    Clinical Protocols
    Luteinizing Hormone
    Infertility
    Fertility
    Ovary
    Embryonic Structures
    Mothers
    Technology

    Keywords

    • Aging
    • Aneuploidy
    • Embryo development
    • Infertility
    • Oocyte maturation
    • Ornithine decarboxylase
    • Putrescine

    ASJC Scopus subject areas

    • Reproductive Medicine
    • Genetics
    • Obstetrics and Gynecology
    • Developmental Biology
    • Genetics(clinical)

    Cite this

    Can peri-ovulatory putrescine supplementation improve egg quality in older infertile women? / Tao, Yong; Tartia, Alina; Lawson, Maralee; Zelinski, Mary; Wu, Wei; Liu, Jia Yin; Smitz, Johan; Léveillé, Marie Claude; Leader, Arthur; Wang, Hongmei; Ramsay, Timothy; Liu, X. Johné.

    In: Journal of Assisted Reproduction and Genetics, 01.01.2018.

    Research output: Contribution to journalArticle

    Tao, Yong ; Tartia, Alina ; Lawson, Maralee ; Zelinski, Mary ; Wu, Wei ; Liu, Jia Yin ; Smitz, Johan ; Léveillé, Marie Claude ; Leader, Arthur ; Wang, Hongmei ; Ramsay, Timothy ; Liu, X. Johné. / Can peri-ovulatory putrescine supplementation improve egg quality in older infertile women?. In: Journal of Assisted Reproduction and Genetics. 2018.
    @article{6dfdfac114b84b00a12344ac9431630c,
    title = "Can peri-ovulatory putrescine supplementation improve egg quality in older infertile women?",
    abstract = "The aging-related decline in fertility is an increasingly pressing medical and economic issue in modern society where women are delaying family building. Increasingly sophisticated, costly, and often increasingly invasive, assisted reproductive clinical protocols and laboratory technologies (ART) have helped many older women achieve their reproductive goals. Current ART procedures have not been able to address the fundamental problem of oocyte aging, the increased rate of egg aneuploidy, and the decline of developmental potential of the eggs. Oocyte maturation, which is triggered by luteinizing hormone (LH) in vivo or by injection of human chorionic gonadotropin (hCG) in an in vitro fertilization (IVF) clinic, is the critical stage at which the majority of egg aneuploidies arise and when much of an egg’s developmental potential is established. Our proposed strategy focuses on improving egg quality in older women by restoring a robust oocyte maturation process. We have identified putrescine deficiency as one of the causes of poor egg quality in an aged mouse model. Putrescine is a biogenic polyamine naturally produced in peri-ovulatory ovaries. Peri-ovulatory putrescine supplementation has reduced egg aneuploidy, improved embryo quality, and reduced miscarriage rates in aged mice. In this paper, we review the literature on putrescine, its occurrence and physiology in living organisms, and its unique role in oocyte maturation. Preliminary human data demonstrates that there is a maternal aging-related deficiency in ovarian ornithine decarboxylase (ODC), the enzyme responsible for putrescine production. We argue that peri-ovulatory putrescine supplementation holds great promise as a natural and effective therapy for infertility in women of advanced maternal age, applicable in natural conception and in combination with current ART therapies.",
    keywords = "Aging, Aneuploidy, Embryo development, Infertility, Oocyte maturation, Ornithine decarboxylase, Putrescine",
    author = "Yong Tao and Alina Tartia and Maralee Lawson and Mary Zelinski and Wei Wu and Liu, {Jia Yin} and Johan Smitz and L{\'e}veill{\'e}, {Marie Claude} and Arthur Leader and Hongmei Wang and Timothy Ramsay and Liu, {X. John{\'e}}",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1007/s10815-018-1327-x",
    language = "English (US)",
    journal = "Journal of Assisted Reproduction and Genetics",
    issn = "1058-0468",
    publisher = "Springer New York",

    }

    TY - JOUR

    T1 - Can peri-ovulatory putrescine supplementation improve egg quality in older infertile women?

    AU - Tao, Yong

    AU - Tartia, Alina

    AU - Lawson, Maralee

    AU - Zelinski, Mary

    AU - Wu, Wei

    AU - Liu, Jia Yin

    AU - Smitz, Johan

    AU - Léveillé, Marie Claude

    AU - Leader, Arthur

    AU - Wang, Hongmei

    AU - Ramsay, Timothy

    AU - Liu, X. Johné

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - The aging-related decline in fertility is an increasingly pressing medical and economic issue in modern society where women are delaying family building. Increasingly sophisticated, costly, and often increasingly invasive, assisted reproductive clinical protocols and laboratory technologies (ART) have helped many older women achieve their reproductive goals. Current ART procedures have not been able to address the fundamental problem of oocyte aging, the increased rate of egg aneuploidy, and the decline of developmental potential of the eggs. Oocyte maturation, which is triggered by luteinizing hormone (LH) in vivo or by injection of human chorionic gonadotropin (hCG) in an in vitro fertilization (IVF) clinic, is the critical stage at which the majority of egg aneuploidies arise and when much of an egg’s developmental potential is established. Our proposed strategy focuses on improving egg quality in older women by restoring a robust oocyte maturation process. We have identified putrescine deficiency as one of the causes of poor egg quality in an aged mouse model. Putrescine is a biogenic polyamine naturally produced in peri-ovulatory ovaries. Peri-ovulatory putrescine supplementation has reduced egg aneuploidy, improved embryo quality, and reduced miscarriage rates in aged mice. In this paper, we review the literature on putrescine, its occurrence and physiology in living organisms, and its unique role in oocyte maturation. Preliminary human data demonstrates that there is a maternal aging-related deficiency in ovarian ornithine decarboxylase (ODC), the enzyme responsible for putrescine production. We argue that peri-ovulatory putrescine supplementation holds great promise as a natural and effective therapy for infertility in women of advanced maternal age, applicable in natural conception and in combination with current ART therapies.

    AB - The aging-related decline in fertility is an increasingly pressing medical and economic issue in modern society where women are delaying family building. Increasingly sophisticated, costly, and often increasingly invasive, assisted reproductive clinical protocols and laboratory technologies (ART) have helped many older women achieve their reproductive goals. Current ART procedures have not been able to address the fundamental problem of oocyte aging, the increased rate of egg aneuploidy, and the decline of developmental potential of the eggs. Oocyte maturation, which is triggered by luteinizing hormone (LH) in vivo or by injection of human chorionic gonadotropin (hCG) in an in vitro fertilization (IVF) clinic, is the critical stage at which the majority of egg aneuploidies arise and when much of an egg’s developmental potential is established. Our proposed strategy focuses on improving egg quality in older women by restoring a robust oocyte maturation process. We have identified putrescine deficiency as one of the causes of poor egg quality in an aged mouse model. Putrescine is a biogenic polyamine naturally produced in peri-ovulatory ovaries. Peri-ovulatory putrescine supplementation has reduced egg aneuploidy, improved embryo quality, and reduced miscarriage rates in aged mice. In this paper, we review the literature on putrescine, its occurrence and physiology in living organisms, and its unique role in oocyte maturation. Preliminary human data demonstrates that there is a maternal aging-related deficiency in ovarian ornithine decarboxylase (ODC), the enzyme responsible for putrescine production. We argue that peri-ovulatory putrescine supplementation holds great promise as a natural and effective therapy for infertility in women of advanced maternal age, applicable in natural conception and in combination with current ART therapies.

    KW - Aging

    KW - Aneuploidy

    KW - Embryo development

    KW - Infertility

    KW - Oocyte maturation

    KW - Ornithine decarboxylase

    KW - Putrescine

    UR - http://www.scopus.com/inward/record.url?scp=85057194099&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85057194099&partnerID=8YFLogxK

    U2 - 10.1007/s10815-018-1327-x

    DO - 10.1007/s10815-018-1327-x

    M3 - Article

    JO - Journal of Assisted Reproduction and Genetics

    JF - Journal of Assisted Reproduction and Genetics

    SN - 1058-0468

    ER -